Page 2 - Aging Program News Today

Two recently approved treatments offer newfound hope for patients in the early stages of Alzheimer's disease, but most people who could benefit will likely be deemed ineligible, a new study finds.

Only a small percentage of people with early AD may be eligible to receive treatment, mostly due to chronic health conditions and brain scan abnormalities common in older adults.

If the FDA grants Lecanemab full approval, medical experts say Medicaid and Medicare will likely cover it

In an eight-year study of more than 600 community-dwelling older adults, Johns Hopkins Medicine researchers say they have further linked levels of cell-free DNA (DNA fragments resulting from cell death) circulating in the blood to chronic inflammation and frailty.

Sessions in June and July

Sessions in June and July

Sessions in June and July

Sessions in June and July

Sessions in June and July

Sessions in June and July